Advice
On 16 March, 2015, the Medicines and Healthcare Products Regulatory Agency (MHRA) published a statement advising that, due to a change in the mode of administration, Takeda has made the decision to withdraw the marketing authorisation in the EU for ferumoxytol (Riensol), for the intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease.
Please see link to MHRA statement
Medicine details
- Medicine name:
- ferumoxytol (Rienso)
- SMC ID:
- 833/13
- Indication:
- For the intravenous treatment of iron deficiency anaemia (IDA) in adult patients with chronic kidney disease (CKD).
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 11 February 2013